|
|
Article: CytRx Raises $37M, Reducing Stake In RXi RNAi Subsidiary.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Staff Writer
CytRx Corp. entered agreements to raise $37 million in a private placement, a move that will satisfy conditions of recent licensing deals made by its RNA interference-based subsidiary.
At least $15 million of the proceeds will be invested in the subsidiary, RXi Pharmaceuticals Corp., to which CytRx previously transferred its RNAi assets. RXi in January entered additional RNAi-based deals with the University of Massachusetts Medical School, deals that were contingent on funding and CytRx reducing its stake in RXi to a minority position.
Steven Kriegsman, president and CEO of Los Angeles-based CytRx, said CytRx will reduce its stake ...
Related newspaper, magazine, and journal articles:
|
|
Article: BIOWORLD TODAY READER SURVEY.
BIOWORLD Today;
January 26, 1999 ;
396 words
... ... The results will be used to improve BioWorld Today. Name: Title: Company: Phone ... provided. 1. What is your opinion of BioWorld Today? How has the newsletter helped you ... 3. What publications, other than BioWorld Today, do you turn to for biotechnology ...
|
|